In after-hours trading on Friday, Silverback Therapeutics Inc. (SBTX) saw its shares price dip -16.43 percent to $32.00. As of Friday’s close, Silverback shares were down -3.47%. In the past 50 days, the average daily volume has been 140K shares, and the stock volume remained 0.55 million shares.

Since the beginning of the quarter, SBTX stock has decreased by -32.36%, but has stabilized in the past week. The current market cap of SBTX is $1.16 billion, and its outstanding shares were 34.77 million. Because the SBTX stock declined in the absence of recent news, we can then provide a deeper understanding of SBTX by referring to recent developments.

What’s the latest at SBTX?

Biopharmaceutical company Silverback Therapeutics develops drugs that can be delivered systemically and tissue-targeted for the treatment of cancer, chronic viral infections, and other serious diseases based on its unique ImmunoTAC technology platform.

By combining proprietary payloads with monoclonal antibodies targeting specific disease sites, SBTX’s platform is able to modulate key disease modifying pathways. Silverback is initially developing targeted immuno-oncology agents that target the tumor microenvironment with a TLR8 agonist myeloid cell activator in order to kill cancer cells.

Silverback attended the Raymond James Human Health Innovation Conference last week. During Wednesday, June 23rd’s presentation, SBTX’s Chief Executive Officer, Laura Shawver, Ph.D., provided a company overview.

SBTX made the presentation available live via the website and a webcast replay is available for 30 days at the site. The management team of SBTX also attended the conference in addition to hosting investor meetings.

Last month, Silverback reported financial results for the first quarter ended March 31, 2021.

First Quarter Financial Results:

• SBTX posted a net loss of $18.9 million, compared with a loss of $5.3 million a year ago.
• Non-cash stock-based compensation expense of $4.3 million compared to $47,000 during the same period last year drove the loss.
• According to the report, the R&D expenses of SBTX were $12.2 million, as compared to $4.4 million for the same period in 2020.
• During 2021, SBTX’s research and development expenses, including those associated with SBT6290 and SBT8230, increased in large part due to the advancement of pipeline programs.
• SBTX spent $6.6 million on general and administrative expenses, compared to $0.8 million last year.
• In addition to higher personnel expenses in 2020, including new executives, and increased salary, bonus, and stock compensation, the increases in general and administrative costs are primarily due to increased headcount.

Is the liquidity of SBTX is strong enough?

Silverback (SBTX) had $374.2 million in cash and cash equivalents at March 31, 2021, compared with $386.6 million at December 31, 2020. Within the next 24 months, these funds will be sufficient to cover all SBTX’s operating expenses and capital expenditures.